Our objective is to evaluate and optimize Bovi-MV formulation through its effect on serum mineral/vitamin (M/V) concentrations in cattle and develop a systems approach to oral M/V supplementation through the lifecycle of beef cattle to determine the best management strategy to help reduce M/V deficiencies in young and mature animals. Cow/calf pairs (n = 300 over 2 yr) and follow the calves to harvest late in yr 2. The research is timed to coincide with typical management handling processes (e.g., vaccination of cows before calving and calf processing after birth, before pasture, at weaning time, on induction to the feedlot, and at reimplanting). The calf herd will be divided at birth into treatment (calves whose dams received BoviMV supplement) and control (~150 calves per group). Vitaferst-Care will be provided to the treatment group at processing (vaccination, antiparasitic application) before going to grass (~ 3 mo of age). Bovi-MV will only be given to the treatment group. All calves will be administered a tracer vaccine to assess their immune response. Blood samples will be collected from all calves for antibody titer testing at weaning (~ 6 mo of age). The treatment calves will also receive a booster dose of Bovi-MV at that time. Approximately 90 d after weaning (~ 9 mo of age) antibody titer will be determined immune response was. Calf morbidity, mortality, and performance (average daily gain) will be monitored in the feedlot. An accredited lab will conduct M/V blood analysis; antibody titer testing will be done at a Lakeland College lab. Based on MV and titer to the Bovi-MV supplement and tracer vaccine, the formulation of the Bovi-MV will be evaluated, and recommendations will be made. Based on results from two previous studies evaluating M/V blood concentrations in cattle (Neonatal supplement and Itchy Cow) in Western Canada, vitamin and mineral concentrations tended to be below optimum values, especially in herds provided supplementation free choice. All cows were deficient in vitamin A at calving, averaging 66.27 ± 2.51 ppb, with 50% having nondetectable concentrations. With vitamin E, 8 animals had nondetectable concentrations, only 8 had sufficient concentrations, and those with detectable concentrations averaged 3.16 ppm ± 2.17. Cows had sufficient iron ug/mL averaging 2.14 ± 1.02 and selenium ug/mL 0.09 ± 0.02. As Cheryl Waldner et al. (2023) reported, 24 to 43% copper deficiency is prevalent in cattle in the southern halves of the three prairie provinces. Armed with this information, this study is the first step in developing a systems approach to year-round management of the cow herd’s vitamin and mineral supplementation.

中文翻译：

---

PSLBII-1 通过有针对性的补充剂优化和评估提高牛的健康和生产性能


我们的目标是通过其对牛血清矿物质/维生素 （M/V） 浓度的影响来评估和优化 Bovi-MV 配方，并开发一种在肉牛的整个生命周期中口服 M/V 补充剂的系统方法，以确定最佳管理策略，以帮助减少年轻和成熟动物的 M/V 缺乏症。奶牛/犊牛配对（2 年 n = 300 只），并跟随犊牛在 2 年晚些时候收获。该研究的时间安排与典型的管理处理过程（例如，奶牛产犊前的疫苗接种和出生后的犊牛加工、放牧前、断奶时、诱导饲养场和再植入时）相吻合。犊牛群在出生时将分为治疗型（母牛接受 BoviMV 补充剂的犊牛）和对照（每组 ~150 头犊牛）。在上草地（~ 3 个月大）之前，将在加工（疫苗接种、抗寄生虫应用）时向治疗组提供 Vitaferst-Care。Bovi-MV 将仅给予治疗组。所有犊牛都将接种示踪剂疫苗以评估其免疫反应。将从所有犊牛身上采集血样，以便在断奶时（~ 6 个月大）进行抗体滴度测试。届时，接受治疗的犊牛也将接受 Bovi-MV 的加强剂量。断奶后约 90 天 （~ 9 个月龄） 抗体滴度将确定免疫反应为。犊牛的发病率、死亡率和生产性能（平均日增重）将在饲养场进行监测。经认可的实验室将进行 M/V 血液分析;抗体滴度测试将在莱克兰学院实验室进行。根据 MV 和 Bovi-MV 补充剂和示踪剂疫苗的滴度，将评估 Bovi-MV 的配方，并提出建议。 根据之前两项评估加拿大西部牛 M/V 血液浓度（新生儿补充剂和瘙痒奶牛）的研究结果，维生素和矿物质浓度往往低于最佳值，尤其是在提供免费补充剂选择的牛群中。所有奶牛在产犊时都缺乏维生素 A，平均为 66.27 ± 2.51 ppb，其中 50% 的浓度检测不到。使用维生素 E，8 只动物的浓度检测不到，只有 8 只动物的浓度足够，可检测浓度的动物平均为 3.16 ppm ± 2.17。奶牛的铁含量为 2.14 ug/mL，平均为 2.14 ± 1.02，硒含量为 0.09 ± 0.02。正如 Cheryl Waldner 等人（2023 年）报道的那样，三个草原省份南半部的牛普遍存在 24% 至 43% 的铜缺乏症。有了这些信息，这项研究是开发系统方法的第一步，以全年管理奶牛群的维生素和矿物质补充剂。